Job creations
As the macro pressures of higher rates and fear of recession build, today’s investor is increasingly risk averse. With zero-risk options offering decent returns, only the highest-quality programs will get funding.
On Rare Disease Day, Feburary 28, AstraZeneca announced the creation of the Alexion, AstraZeneca Rare Disease Development Hub in Toronto, Ontario.
Whether a job search is voluntary or not, months of interviews, wrangling over pay and benefits and evaluating options has a weighty psychological toll.
Amgen opened a new research and development site in San Francisco Bay, while Enzo Biochem opened a 100,000 square foot laboratory and research facility in New York
Sonoma Bio announced its plans to erect an 83,000-square-foot operations facility in Seattle, while Thermo Fisher opened a new viral vector manufacturing plant in Massachusetts.
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
The layoffs trend in the life sciences industry is continuing into the final months of 2022. See inside for details on which companies are reducing staff to increase cash flow.
Astellas is investing around $70 million, providing lab and co-working spaces to support current and future growth initiatives in the cell and gene therapy space for cancer and rare diseases.
Pfizer is looking to strengthen its grip on mRNA research and development with a $470 million new facility, and Eikon is planning to open a 25,000 facility. Both will be based in New York.
Cambridge, Massachusetts’ Kendall Square just got a little more crowded following the announcement that life sciences giant Bayer opened its new Research and Innovation Center.
PRESS RELEASES
